All In Biotech

Drug Trial Radar · NCT05016609

Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)

Same-visit Hepatitis C Testing and Treatment to Accelerate Cure Among People Who Inject Drugs: a Cluster Randomised Control Trial (The QuickStart Study)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,800 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,800

Planned (sponsor's estimate)

Start

Mar 9, 2022

Primary completion

Apr 2024

Study completion Jun 2024

Sponsor

Sponsor type
Academic, hospital or other
First posted
Aug 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Health services research
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The QuickStart study aims to assess the impact of three models of HCV care on HCV treatment uptake and cure among people who inject drugs. Rapid point-of-care (POC) HCV testing and test-and-treat strategies will be utilised in primary health care settings across Australia.

Conditions

  • Hepatitis C

Interventions

  • OraQuick HCV Antibody test (OraSure Technologies, Inc)Device

    The OraQuick HCV test is a point of care antibody test for detecting HCV antibodies in fingerstick blood. The test takes 20 minutes to provide a result. Appropriate pre- and post-test counselling will be provided to participants.

  • Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)Device

    Xpert® HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Only participants who return a reactive OraQuick HCV Antibody test will be offered the Xpert® HCV VL Fingerstick test. Appropriate pre- and post-test counselling will be provided to participants.

  • Sofosbuvir/Velpatasvir (Gilead)Drug

    Participants with a detectable HCV antibody will be offered treatment with sofosbuvir/velpatasvir.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HCV treatmentTime frame: Within 12 weeks of enrolment
  2. HCV cureTime frame: HCV cure will be measured between 4 and 20 weeks post treatment completion.

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Mediclinic Australia

    Clayton South, Victoria, Australia · Recruiting

  • Innerspace

    Collingwood, Victoria, Australia · Recruiting

  • Corio Community Health Centre

    Corio, Victoria, Australia · Recruiting

  • Cohealth Fitzroy

    Fitzroy, Victoria, Australia · Recruiting

  • Homeless Healthcare

    Highgate, Western Australia, Australia · Recruiting

  • Cockburn Wellbeing

    Success, Western Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.